|
|
Post by magnus123 on Jun 30, 2020 9:05:44 GMT
I would like to introduce you to Interpace Biosciences, a low float micro cap with growing revenues and covid 19 antibody test developed. Company profile: Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. They had a 1:10 stock split in january. Market Cap $19.38M Total Debt $4.08M Cash $13.37M Current PPS: $4.80 Shares outstanding 4,036,595 (Institutional ownership at 18.90%) Revenue (TTM) 27.27M They are performing at a loss, but with a growing business and a serology antibody test against Coronavirus developed, this could be explosive reflecting the low market cap and low float. I plan to buy a position today. Here is a seeking alpha article from 15 January 2020 Underappreciated Drivers Bargain Valuation ....pdf (613.01 KB) |
|
|
|
Post by magnus123 on Jun 30, 2020 9:39:03 GMT
|
|
|
|
Post by JHam on Jun 30, 2020 11:31:32 GMT
I would like to introduce you to Interpace Biosciences, a low float micro cap with growing revenues and covid 19 antibody test developed. Company profile: Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. They had a 1:10 stock split in january. Market Cap $19.38M Total Debt $4.08M Cash $13.37M Current PPS: $4.80 Shares outstanding 4,036,595 (Institutional ownership at 18.90%) Revenue (TTM) 27.27M They are performing at a loss, but with a growing business and a serology antibody test against Coronavirus developed, this could be explosive reflecting the low market cap and low float. I plan to buy a position today. Here is a seeking alpha article from 15 January 2020 Thanks for introducing this one. I’ve seen some people I follow at ST mention this one a few times. I definitely like the low float aspect. I have a plan at the moment that I’m trying to stick to, but if this is still trading in the $4s in a few weeks then I may take a small gamble. Do you know their burn rate? Will they need to raise cash any time soon? |
|
|
|
Post by magnus123 on Jun 30, 2020 12:23:40 GMT
Thanks for introducing this one. I’ve seen some people I follow at ST mention this one a few times. I definitely like the low float aspect. I have a plan at the moment that I’m trying to stick to, but if this is still trading in the $4s in a few weeks then I may take a small gamble. Do you know their burn rate? Will they need to raise cash any time soon? They have a negative adjusted EBITDA of 4.1 Million. From the last CC: "In March, we reduced lab costs, discretionary and non essential spending. We decreased salary, employee wages by 10% to 15% starting in mid April. We expect the operating expense to be further reduced in the second quarter of 2020, while volume is expected to remain at reduced levels. As the benefit of integration activities in the second quarter are realized, we will be reorganizing and streamlining recurring finance and accounting costs in the third and fourth quarter of 2020." "We used $7.1 million of cash from operating activities as compared to $3 million in the first quarter of 2019." "As of June 17, 2020, we had a cash position of approximately $16.2 million and borrowings under our line of credit amounting to $3.4 million." (More cash than i have written in the initial post) "During June, we are seeing that our business, while down approximately 30% from where we were just prior to the pandemic hitting, is recovering nicely and largely as we anticipated. We feel that the worst is behind us." (Due to decreased testing activites etc. during the lockdown, clinicians and physicians slowed down testing. This is recovering right now.) "At this time, due to uncertainty we are not in a position to provide you with a confident revenue projection for the remainder of 2020. However, we are projecting net revenue for the second quarter of 2020 to be between $5.5 million and $6 million." I don't believe that they will raise cash in the near future. They had an offering in Q1 and have a lot of cash now. They are working on reducing expenses while growing the business. The pandemic was hard for them so far, but the business is recovering. The PPS has still not recovered from the losses in March. An offering is of course possible later this year. |
|
|
|
Post by magnus123 on Jun 30, 2020 16:58:49 GMT
For full disclosure, i bought an initial stake now on the dip.
|
|
|
|
Post by magnus123 on Jul 1, 2020 20:59:59 GMT
For full disclosure, i bought an initial stake now on the dip. Added again at 4.38. I'm done now so far. Will only buy more, if it goes under $4 for no reason. |
|
|
|
Post by magnus123 on Jul 1, 2020 21:13:36 GMT
I have no idea why, but IDXG is up more than 20% on heavy volume. There is no news or other apparent reason.
|
|
|
|
Post by JHam on Jul 2, 2020 2:13:50 GMT
I have no idea why, but IDXG is up more than 20% on heavy volume. There is no news or other apparent reason. Yeah, I see that! Maybe some news is about to hit in the AM tomorrow. Sadly I wasn’t able to open a position here yet. |
|
|
|
Post by magnus123 on Jul 9, 2020 20:20:25 GMT
I am back in here with a starter position at $5.21.
|
|
|
|
Post by magnus123 on Jul 21, 2020 10:28:31 GMT
|
|
|
|
Post by JHam on Jul 21, 2020 10:34:03 GMT
Nice! I was sooo close to buying this early last week when it went back in the $4s, but added CPSH instead. Mistake in the short term for me. Oh well. Congrats though. I hope it takes off today! |
|
|
|
Post by magnus123 on Jul 21, 2020 10:48:36 GMT
Nice! I was sooo close to buying this early last week when it went back in the $4s, but added CPSH instead. Mistake in the short term for me. Oh well. Congrats though. I hope it takes off today! I also missed the $4s to average down. I will likely sell IDXG today to buy more CPSH while it's cheap. |
|
